ABSTRACT
Objective:By comparing the clinical outcome of the modified triple tube method and the traditional three-tube method in the treatment of thoracic internal fistula after esophageal cancer surgery, in order to provide a basis for the clinical treatment of thoracic fistula after esophageal cancer surgery.Methods:The traditional three-tube method for the treatment of thoracic fistula after esophageal cancer surgery was the traditional group, and the modified three-tube method was the modified group. There was no spillover of the contrast agent during the above gastrointestinal angiography and the patient could eat normally as the standard of cure. In this study, we collected the data of thoracic fistula patients after esophageal cancer surgery who were treated with two kinds of treatment methods in our hospital in different time period(the traditional group: 10 patients from February 2008 to June 2014; the modified group: 36 patients from January 2012 to December 2019). Retrospective analysis of the two groups of patients in terms of general data(sex, age, etiology and other factors), time to cure and other indicators, compare the pros and cons of these two methods in the treatment of postoperative thoracic fistula.Results:There was no significant difference in general data such as sex, age, and cure time between the two groups, but there was significant difference in the cure time( P<0.01). The average cure time of the modified group was(38.08±11.97) days, which was significantly better than that of the traditional group(95.60 ± 7.79) days. Conclusion:Compared with the traditional three-tube method, the modified three-tube method can significantly shorten the treatment time when treating patients with thoracic fistula after esophageal cancer surgery.
ABSTRACT
Primary pulmonary mucinous adenocarcinoma with a low incidence,a subtype of lung adeno-carcinoma,occurs in adult males because of its no significant clinical specificity,likely to cause misdiagnosis,and patients with adverse prognosis.Thus,we need further to understand this disease and early diagnosis through a va-riety of methods as soon as possible.Surgical treatment is still the preferred mode of this disease.With addition to resecting lesions,it is also further pathological diagnosis,gene testing,tumor staging and prognosis as well as prep-aration for following-up chemotherapy.In recent years,with the continuous development of genetic technology and innovation,the occurrence of this disease has been found to be related to KRAS gene mutation,ALK gene re-arrangement and its related signal pathway.Related gene mutations and signaling pathways can serve as a target for the treatment of this disease,which provides a variety of ideas for the development of new targeted drugs.How-ever,there are still many problems that need further study,including standard chemotherapy for primary pulmona-ry mucinous adenocarcinoma,drug resistance to targeted drugs, and the development of new KRAS inhibitors.This article reviews the definition of primary pulmonary mucinous adenocarcinoma and pathogenesis,diagnosis and some of the latest treatment methods.
ABSTRACT
Primary pulmonary mucinous adenocarcinoma with a low incidence,a subtype of lung adeno-carcinoma,occurs in adult males because of its no significant clinical specificity,likely to cause misdiagnosis,and patients with adverse prognosis.Thus,we need further to understand this disease and early diagnosis through a va-riety of methods as soon as possible.Surgical treatment is still the preferred mode of this disease.With addition to resecting lesions,it is also further pathological diagnosis,gene testing,tumor staging and prognosis as well as prep-aration for following-up chemotherapy.In recent years,with the continuous development of genetic technology and innovation,the occurrence of this disease has been found to be related to KRAS gene mutation,ALK gene re-arrangement and its related signal pathway.Related gene mutations and signaling pathways can serve as a target for the treatment of this disease,which provides a variety of ideas for the development of new targeted drugs.How-ever,there are still many problems that need further study,including standard chemotherapy for primary pulmona-ry mucinous adenocarcinoma,drug resistance to targeted drugs, and the development of new KRAS inhibitors.This article reviews the definition of primary pulmonary mucinous adenocarcinoma and pathogenesis,diagnosis and some of the latest treatment methods.